IDST for BTKi AEs
Interactive Tool to Guide Management of Adverse Events With BTK Inhibitor Therapy in Hematologic Malignancies

Released: January 07, 2025

Expiration: January 06, 2026

References

Acalabrutinib [prescribing information]. FDA. Wilmington, DE: AstraZeneca; 2024.

Acalabrutinib [prescribing information]. EMA. Södertälje, Sweden: AstraZeneca AB; 2024.

American Society of Hematology COVID-19 Resources. Prevention of COVID-19 in immunocompromised patients with hematologic conditions. Updated on April 6, 2023. https://www.hematology.org/covid-19/archived-resources-for-clinicians/prevention-of-covid-19-in-immunocompromised-patients-with-hematologic-conditions. Accessed Dec 20, 2024.

American Society of Hematology COVID-19 Resources. Treatment of COVID-19 in Immunocompromised Patients With Hematologic Conditions. Updated on Sept 13, 2022. https://www.hematology.org/covid-19/archived-resources-for-clinicians/prevention-of-covid-19-in-immunocompromised-patients-with-hematologic-conditions. Accessed Dec 20, 2024.

Awan FT, Al-Sawaf O, Fischer K, Woyach JA. Current perspectives on therapy for chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:1-10.

Awan FT, Addison D, Alfraih F, et al. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. Blood Adv. 2022;6:5516-5525.

Bercusson A, Colley T, Shah A, et al. Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018;132:1985-1988.

Blez D, Blaize M, Soussain C, et al. Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus. Haematologica. 2020;1305:478-489.

Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796-1805.

Brown JR, Byrd JC, Ghia P, et al. Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with chronic lymphocytic leukemia (CLL). Presented at: 2020 American Society of Hematology annual meeting; December 5-8, 2020. Abstract 3146.

Brown JR, Byrd JC, Ghia P, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2021;107:1335-1346.

Brown JR, Byrd JC, Chia Paolo, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022;107:1335-1346.

Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319-332.

Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425-2437.

Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib vs ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-223.

Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323-332.

Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135:1204-1213.

Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441-3452.

Chen ST, Azali L, Rosen L, et al. Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. Hematol Oncol. 2022;15:92.

Coombs CC, Shah NN, Jurczak W, et al. Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 7513.

Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3:1799-1807.

Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134:1919-1928.

de Jong J, Hellemans P, De Wilde S, et al. A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. Leuk Lymphoma. 2018;59:2888-2895.

de Zwart L, Snoeys J, De Jong J, et al. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther. 2016;100:548-557.

Dimopoulos MA, Opat S, D'Sa S, et al. Zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia: final analysis from the randomized phase III ASPEN study. J Clin Oncol. 2023;41:5099-5106.

Geethakumari PR, Awan F. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. Expert Rev Hematol. 2020;13:1039-1046.

Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131:1955-1959.

Ibrutinib [prescribing information]. FDA. South San Francisco, CA: Pharmacyclics; 2024.

Ibrutinib [prescribing information]. EMA. Beerse, Belgium: Janssen-Cilag International NV; 2024.

Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129:2581-2584.

Li C, Chen L, Li L, Chen W. Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models. Eur J Pharm Sci. 2023;189:106564.

Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020;2020:336-345.

Mato AR, Islam P, Daniel C, et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood. 2016;127:1064-1067.

Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892-901.

Mato AR, Woyach JA, Brown JR, et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: additional patients and extended follow-up of from the phase I/2 BRUIN study. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 961.

McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829-3830.

National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed July 24, 2023.

National Comprehensive Cancer Network. Cancer and COVID-19 vaccination. Recommendations of the National Comprehensive Cancer Network® (NCCN®) COVID-19 Vaccination Advisory Committee. V.8.0. nccn.org. Accessed July 24, 2023.

O'Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409-1418.

Paydas S. Management of adverse events/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56-63.

Pirtobrutinib [prescribing information]. FDA. Indianapolis, IN: Lilly USA; 2024.

Pirtobrutinib [prescribing information]. EMA. Utrecht, The Netherlands: Eli Lilly Nederland BV; 2023.

Shanafelt TD, Wang XV, Hanson CA, et al. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112-120.

Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab vs chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278-1291.

Sestier M, Hillis C, Fraser G, et al. Bruton’s tyrosine kinase INHIBITORS AND CARDIOTOXICITY: MORE THAN JUST ATRIAL FIBRILLATION. Curr Oncol Rep. 2021;23:113.

Seymour JF, Byrd JC, Ghia Paolo, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR. Blood. 2023;142:687-699.

Siontis KC, Gersh BJ, Killian JM, et al. Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: characteristics and prognostic implications. Heart Rhythm. 2016;13:1418-1424.

St-Pierre F and Ma S. Use of BTK inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a practical guidance. Blood Lymphat Cancer. 2022;12:81-98.

Tam CS, Opat S, Zhu J, et al. Pooled analysis of safety data from monotherapy studies of the Bruton tyrosine kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies. Presented at: 2019 European Hematology Association annual meeting; June 13-16, 2019a. Abstract PS1159.

Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019b;134:851-859.

Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136:2038-2050.

Tam CSL, Garcia-Sanz, Opat S, et al. ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM). J Clin Oncol. 2022a;40:7521.

Tam CSL, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022b;6:1296-1308.

Tang CPS, Lip GYH, McCormack T, et al. Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Br J Haematol. 2022;196:70-78.

Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136:2027-2037.

Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2024;45:3314-3414.

Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507-516.

Wang ML, Blum KA, Martin P. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739-745.

Wang M, Rule S, Zinzani PL, et al. Long‑term follow‑up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma. Presented at: 2018 American Society of Hematology annual meeting; December 1-4, 2018. Abstract 2876.

Wang M, Rule S, Zinzani PL, et al. Acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Presented at: 2020 American Society of Hematology annual meeting; December 5-8, 2020. Abstract 2040.

Wang ML, Shah NN, Jurczak, et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase I/II BRUIN study. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 4218.

Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens vs chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517-2528.

Zanubrutinib [prescribing information]. FDA. San Mateo, CA: BeiGene USA; 2024.

Zanubrutinib [prescribing information]. EMA. Dublin, Ireland: BeiGene Ireland Ltd; 2024.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Tool to Guide Management of Adverse Events With BTK Inhibitor Therapy in Hematologic Malignancies” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices in monitoring and managing adverse events that can occur in patients with cancer treated with BTK inhibitor therapy with expert guidance from: Toby A Eyre, MBChB, MD; Arnon Kater, MD, PhD; Vincent Ribrag, MD; Stephan Stilgenbauer, MD; and Alessandra Tedeschi, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Tool to Guide Management of Adverse Events With BTK Inhibitor Therapy in Hematologic Malignancies” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content